How India Exports Fenofibrate to the World

In the United States, fenofibrate is approved for the treatment of hypercholesterolemia and hypertriglyceridemia. The FDA has granted numerous Abbreviated New Drug Applications (ANDAs) for generic versions of fenofibrate, indicating a competitive market landscape. Notably, Teva Pharmaceutical Industries received final FDA approval for its generic fenofibrate tablets (54 mg and 160 mg) in May 2005. This approval followed a court ruling that Teva's product did not infringe upon existing patents.

The substantial number of approved ANDAs reflects a robust generic market, aligning with the presence of 168 active Indian exporters supplying fenofibrate to the U.S. This competitive environment underscores the importance of maintaining stringent quality standards and regulatory compliance to ensure market access.

In the European Union, fenofibrate is authorized for use in combination with simvastatin under the brand name Cholib, with the European Commission granting marketing authorization on August 26, 2013. (ema.europa.eu) The European Medicines Agency (EMA) recommends fibrates, including fenofibrate, as second-line treatments, primarily for patients with severe hypertriglyceridemia or those intolerant to statins. (ema.europa.eu) Manufacturers exporting to the EU and UK must adhere to Good Manufacturing Practice (GMP) standards as outlined by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Fenofibrate is included in the National Essential Medicines Lists of several countries, such as Bhutan and Seychelles, indicating its recognized importance in managing lipid disorders. (cdn.who.int) While not listed on the WHO Model List of Essential Medicines, its inclusion in national lists underscores its therapeutic value. Compliance with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for global market acceptance.

In India, fenofibrate is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines; however, specific ceiling prices for fenofibrate should be verified with the latest NPPA notifications. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for fenofibrate have expired, leading to a competitive generic market. For instance, Teva's generic fenofibrate received FDA approval in May 2005 following a court ruling of non-infringement. This expiration has facilitated the entry of multiple generic manufacturers, intensifying market competition.

In December 2025, the EMA updated the product information for Cholib, a combination of fenofibrate and simvastatin, reflecting new safety data. (ema.europa.eu) This update underscores the importance of continuous pharmacovigilance and compliance with evolving regulatory requirements.

Additionally, in February 2026, the FDA approved a new generic formulation of fenofibrate, further increasing market competition and emphasizing the need for exporters to maintain high-quality standards to remain competitive.

These developments highlight the dynamic nature of the pharmaceutical industry and the necessity for exporters to stay informed about regulatory changes and market trends to ensure sustained success.

India's pharmaceutical industry, including the production of Fenofibrate, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these critical components are sourced from Chinese manufacturers, making the supply chain vulnerable to disruptions stemming from geopolitical tensions, trade disputes, or regulatory changes.

In response to this dependency, the Indian government has initiated measures to bolster domestic production. In November 2024, under the Production Linked Incentive (PLI) scheme, two greenfield plants were inaugurated to manufacture essential molecules like Penicillin G, 6-APA, and Clavulanic Acid, aiming to reduce import reliance by half. However, these efforts are still in nascent stages and have yet to significantly impact the overall supply chain resilience for Fenofibrate.

Our proprietary trade data indicates that the top five Indian exporters of Fenofibrate account for 53.3% of total exports, with ABBOTT HEALTHCARE PRIVATE LIMITED leading at a 14.5% share. This concentration poses a risk, as disruptions affecting these key suppliers could have a disproportionate impact on global supply.

The PLI scheme, launched in 2020, aims to incentivize domestic production of critical APIs and KSMs. While it has led to the establishment of new manufacturing units, the scheme's full impact on reducing supplier concentration and mitigating single-source risks remains to be seen.

Recent geopolitical events have significantly impacted global shipping routes critical to the pharmaceutical supply chain. In February 2026, escalating conflicts led to the effective closure of the Strait of Hormuz, a vital corridor through which approximately 20% of global oil and liquefied natural gas transit. This disruption has caused substantial delays and increased shipping costs, affecting the transportation of APIs and finished pharmaceutical products.

Additionally, tensions in the Red Sea and the Suez Canal have further complicated shipping logistics. Attacks on vessels and subsequent rerouting have added 10 to 14 days to shipping times, exacerbating delays and increasing costs for pharmaceutical shipments from India to key markets.

• Diversify API and KSM Sourcing: Encourage and invest in alternative sources for APIs and KSMs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Manufacturing: Accelerate the implementation and scaling of the PLI scheme to boost domestic production capabilities for critical pharmaceutical components.

• Enhance Supplier Base: Broaden the network of Fenofibrate suppliers to mitigate risks associated with supplier concentration and potential disruptions.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics strategies to navigate geopolitical disruptions affecting major maritime corridors.

• Monitor Regulatory Developments: Stay informed about international regulatory changes and geopolitical events that could impact the pharmaceutical supply chain, enabling proactive risk management.

RISK_LEVEL: HIGH